A nano drug for treating cisplatin resistance in oral squamous cell carcinoma and its preparation method and application
By targeting the nanodrug co-assembled with cisplatin by the polypeptide derivative LEE011-FFERGD and cisplatin, the problem of oral squamous cell carcinoma to cisplatin is solved, the treatment effect is improved, and the efficient enrichment of the drug is achieved in the tumor site. Significantly inhibits tumor growth.
Patent Information
- Application Number
- CN202410258623.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-07
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-03-07
AI Technical Summary
Oral squamous cell carcinoma is severely resistant to cisplatin, resulting in unsatisfactory treatment effect, and its biomarkers and mechanism of action are unclear, which increases the difficulty of treatment.
Prepare a nanodrug, by synthesizing the targeted polypeptide derivative LEE011-FFERGD and cisplatin, the targeted polypeptide derivative can promote silencing of BAG1 gene, reduce the expression of molecules related to the G1/S process in the cell cycle, and reduce drug resistance. Cisplatin acts directly on the diseased site.
The treatment effect of cisplatin on patients with oral squamous cell carcinoma has been improved, and nano-grade drugs have improved drug stability, enriched in the tumor site through high permeability and retention effects, significantly inhibiting tumor growth.
Smart Images

Figure CN118059258B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biology and new medical technology, and in particular to a nano drug for treating cisplatin resistance in oral squamous cell carcinoma, and a preparation method and application thereof. Background Art
[0002] Oral squamous cell carcinoma is the most common oral malignant tumor. It is prone to invasion and metastasis, which greatly harms the patient's quality of life and life. Therefore, its prevention and treatment have always been the focus of oral tumor research. At present, there are three main methods for treating oral squamous cell carcinoma: surgical treatment, radiotherapy and chemotherapy. Among them, chemotherapy is one of the main methods for treating malignant tumors. It has a wide range of applications and rapid effects. It can improve symptoms and improve survival rates for some advanced tumors, making it a very promising method for conquering tumors. Chemotherapy in a broad sense is the process of using chemical drugs to kill pathogens or new organisms inside and outside the body and inhibit their growth and proliferation; chemotherapy in a narrow sense refers to the use of cytotoxic drugs to treat malignant tumors. Since the 1980s, a few malignant tumors have been able to be cured by chemotherapy alone, and for oral squamous cell carcinoma of the head and neck, chemotherapy has also been confirmed by many studies to significantly prolong the patient's survival and improve the patient's quality of life.
[0003] Among the many chemotherapy drugs related to oral squamous cell carcinoma, cisplatin occupies a very important position. Cisplatin (cis-diaminedichloroplatinum, cisplatin, also known as CDDP) is a first-line chemotherapy drug that can be used to treat oral squamous cell carcinoma. However, only about 20%-30% of oral squamous cell carcinoma patients achieve the expected therapeutic effect in cisplatin-based chemotherapy or chemoradiotherapy. The reason is not only that the occurrence of endogenous and acquired drug resistance seriously weakens the efficacy of cisplatin, leading to treatment failure; but also, the specific biomarkers and potential mechanisms of action that lead to cisplatin resistance in oral squamous cell carcinoma are still unclear, which also adds difficulty to the treatment of cisplatin resistance in oral squamous cell carcinoma. Summary of the invention
[0004] In order to solve the above technical problems, the present invention provides a method for preparing a nanomedicine for treating cisplatin-resistant oral squamous cell carcinoma. The drug obtained by the present invention can induce apoptosis of cisplatin-resistant cells of oral squamous cell carcinoma, thereby helping to improve the therapeutic effect of cisplatin on patients with oral squamous cell carcinoma.
[0005] The present invention provides a method for preparing a nano drug for treating cisplatin-resistant oral squamous cell carcinoma, comprising the following steps:
[0006] S1: Synthesize the targeting polypeptide derivative LEE011-FFERGD, the structural formula of the targeting polypeptide derivative LEE011-FFERGD is:
[0007]
[0008] S2: The targeting peptide derivative LEE011-FFERGD in S1 was co-assembled with cisplatin to synthesize the nanodrug LEE011-FFERGD / CDDP.
[0009] Furthermore, the polypeptide derivative LEE011-FFERGD in S1 is obtained by solid phase peptide synthesis using 2-chlorotributyl chloride resin as a carrier and different N-Fmoc protected amino acids as raw materials.
[0010] Furthermore, the specific conditions for assembling and synthesizing the nanodrug LEE011-FFERGD / CDDP in S2 include:
[0011] The targeting polypeptide derivative LEE011-FFERGD is dispersed in PBS buffer (phosphate buffer solution), cisplatin is added, the pH value is adjusted to neutral, and the targeting polypeptide derivative LEE011-FFERGD and cisplatin are heated until both the targeting polypeptide derivative LEE011-FFERGD and cisplatin are dissolved, and the mixture is cooled and allowed to stand to obtain the nano drug of the present invention.
[0012] Furthermore, the pH value is adjusted to be neutral, that is, the pH value range is between 7.3-7.5.
[0013] Furthermore, the concentration of the targeting polypeptide derivative LEE011-FFERGD in PBS buffer is 5 mg / mL.
[0014] Furthermore, the molar concentration of cisplatin is 1 to 3 times the molar concentration of the targeting polypeptide derivative LEE011-FFERGD.
[0015] Furthermore, the solution for adjusting the pH value includes an aqueous solution of sodium carbonate.
[0016] Furthermore, the cooling temperature is 25°C-30°C.
[0017] In the present invention, cooling is performed at room temperature, and cooling to room temperature environment, that is, the cooling temperature is 25°C-30°C.
[0018] Furthermore, the standing time is not less than 30 minutes.
[0019] Furthermore, the steps of the solid phase synthesis method are:
[0020] S11: reacting the swollen 2-chlorotributyl chloride resin with amino acid Fmoc-Asp(tBu)-OH, adding blocking solution; removing the protecting group Fmoc, and washing;
[0021] S12: adding N,N'-dimethylformamide, N,N-diisopropylethylamine, benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate, and amino acid Fmoc-Gly-OH to react, removing the protecting group Fmoc, and washing;
[0022] S13: repeat the step of S12 to sequentially connect the amino acid Fmoc-Arg(Pbf)-OH, the amino acid Fmoc-Glu(tBu)-OH, the amino acid Fmoc-Phe-OH, and the amino acid Fmoc-Phe-OH to the polypeptide;
[0023] S14: adding N,N'-dimethylformamide, LEE011-succinic acid, N,N-diisopropylethylamine, and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate to react;
[0024] S15: washing and cleavage, cleaving the targeted peptide derivative LEE011-FFERGD from the resin.
[0025] Furthermore, the preparation conditions of the swollen 2-chlorotributyl chloride resin in S11 include: placing 0.4 g-0.6 g of 2-chlorotributyl chloride resin in 19 mL-20 mL of dried dichloromethane for 9 min-11 min, and then removing the dichloromethane to obtain the swollen 2-chlorotributyl chloride resin.
[0026] In the present invention, a solid-liquid separation method can be used to remove dichloromethane. In the prior art, technicians can use other conventional methods to remove dichloromethane according to actual conditions.
[0027] Furthermore, the blocking solution is composed of dichloromethane, methanol, and N,N-diisopropylethylamine, and the volume ratio of dichloromethane, methanol, and N,N-diisopropylethylamine is 17:2:1.
[0028] Furthermore, in S11, the time for reacting the swollen 2-chlorotributyl chloride resin with the amino acid Fmoc-Asp(tBu)-OH is 0.5h-1.5h.
[0029] Furthermore, the amount of the amino acid Fmoc-Asp(tBu)-OH in S11 is 0.4 mmol-0.6 mmol.
[0030] Furthermore, the specific process of removing the protecting group Fmoc in S11 includes using 19mL-21mL of anhydrous N,N'-dimethylformamide containing piperidine for a reaction of 0.5h-1h, and the mass fraction of piperidine in the anhydrous N,N'-dimethylformamide is 20%; in the washing in S11, dichloromethane (DCM) is used for washing 3-5 times and then N,N'-dimethylformamide (DMF) is used for washing 3-5 times.
[0031] Furthermore, the washing in S12 is performed by washing with N,N'-dimethylformamide for 3-5 times.
[0032] Furthermore, in the S12, the molar ratio of N,N-diisopropylethylamine, benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate, and amino acid Fmoc-Gly-OH is 2:1:1, and the molar ratio of the amino acid Fmoc-Gly-OH is 0.5 mmol-2 mmol.
[0033] In the present invention, the N,N'-dimethylformamide added in S12 is added as a solvent, and those skilled in the art can select the amount of addition according to actual conditions. Preferably, in order to ensure sufficient reaction, the amount of N,N'-dimethylformamide added is at least 15 mL.
[0034] Furthermore, N,N'-dimethylformamide, N,N-diisopropylethylamine, benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate, and amino acid Fmoc-Gly-OH are added to S12 and the reaction time is 1.5h-2.5h.
[0035] Furthermore, in S13, the ratio of the amount of amino acid Fmoc-Arg(Pbf)-OH, amino acid Fmoc-Glu(tBu)-OH, amino acid Fmoc-Phe-OH, and amino acid Fmoc-Phe-OH to the amount of amino acid Fmoc-Gly-OH is 1:1:1:1:1.
[0036] In the present invention, S13 repeats the step of S12, and the amount of the amino acid Fmoc-Arg(Pbf)-OH, amino acid Fmoc-Glu(tBu)-OH, amino acid Fmoc-Phe-OH, and amino acid Fmoc-Phe-OH used in S13 is the same as the amount of the amino acid Fmoc-Gly-OH in S12.
[0037] Furthermore, in the S14, the molar ratio of N,N-diisopropylethylamine, benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate, and LEE011-succinic acid is 2:1:1, and the molar ratio of LEE011-succinic acid is 0.5 mmol-2 mmol.
[0038] Furthermore, the reaction time of adding N,N'-dimethylformamide, LEE011-succinic acid, N,N-diisopropylethylamine, and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate to S14 is 1.5h-2.5h.
[0039] Furthermore, the method of washing and cutting in S15 to separate the polypeptide derivative includes first washing with dichloromethane for 3-5 times, and then adding 19mL-21mL trifluoroacetic acid for cutting for 0.5-1h to cut the targeted polypeptide derivative LEE011-FFERGD from the resin.
[0040] Furthermore, in the present invention, the separated targeting polypeptide derivative LEE011-FFERGD can be purified by using reverse phase high performance liquid chromatography.
[0041] The invention also provides the nano medicine obtained by the preparation method.
[0042] Furthermore, the nanomedicine is in granular form with an average diameter of 60nm-80nm.
[0043] The present invention also provides application of the nano drug obtained by the preparation method in treating patients with oral squamous cell carcinoma.
[0044] The embodiments of the present invention have the following technical effects:
[0045] 1. The nanomedicine of the present invention, by assembling the targeting polypeptide derivative LEE011-FFERGD and cisplatin, can, on the one hand, silence the BAG1 gene, a related immortality gene, of patients with cisplatin-resistant oral squamous cell carcinoma, thereby affecting the expression level of related molecules in the G1 / S process of the cell cycle, and reducing the resistance of patients with cisplatin-resistant oral squamous cell carcinoma to cisplatin; and the cisplatin in the drug directly acts on the diseased area. It can be seen that the nanomedicine of the present invention, with the cooperation of the targeting polypeptide derivative LEE011-FFERGD and cisplatin, improves the therapeutic effect of the drug on patients with oral squamous cell carcinoma.
[0046] 2. The method for preparing nanomedicine of the present invention is simple and easy to implement, and the nanomedicine obtained by the present invention also has a nanoscale size. Nanoscale drugs are not only beneficial to improving the stability of cisplatin in the body, but also can be enriched in the tumor site through high permeability and retention effect, thereby achieving a better therapeutic effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0048] Figure 1 The transmission electron microscope images of the intermediate product LEE011-FFERGD and the final drug LEE011-FFERGD / CDDP in Example 1 (scale is 500 nm), wherein Figure 1 (a) is a transmission electron micrograph of the intermediate product LEE011-FFERGD. Figure 1 (b) is a transmission electron microscopy image of the final drug LEE011-FFERGD / CDDP.
[0049] Figure 2 is the particle size distribution diagram of the intermediate product LEE011-FFERGD and the final drug LEE011-FFERGD / CDDP in Example 1, wherein Figure 2 (a) is the particle size distribution diagram of the intermediate product LEE011-FFERGD. Figure 2 (b) is the particle size distribution diagram of the final drug LEE011-FFERGD / CDDP.
[0050] Figure 3 is the circular dichroism spectra of the intermediate product LEE011-FFERGD and the final drug LEE011-FFERGD / CDDP of Example 1, wherein Figure 3 (a) is the circular dichroism spectrum of the intermediate product LEE011-FFERGD. Figure 3 (b) is the circular dichroism spectrum of the final drug LEE011-FFERGD / CDDP.
[0051] Figure 4 The results of the drug inhibition experiment of Tca-8113 / CDDP cell clone formation performed in Example 1 and Comparative Examples 1 to 4 are as follows; Figure 4 (a) is a visual result diagram of the drug inhibition of Tca-8113 / CDDP cell clone formation in Example 1 and Comparative Examples 1 to 4. Figure 4(b) is a statistical bar graph of the number of cell clones after drug inhibition of Tca-8113 / CDDP cell clone formation in Example 1 and Comparative Examples 1 to 4; wherein Example 1 is recorded as LEE011-FFERGD / CDDP, Comparative Example 1 is recorded as Vehicle, Comparative Example 2 is recorded as cisplatin, Comparative Example 3 is recorded as LEE011, and Comparative Example 4 is recorded as cisplatin+LEE011.
[0052] Figure 5 The results of the in vivo apoptosis induction experiment of Tca-8113 / CDDP in Example 1 and Comparative Examples 1-3 are shown in FIG. Figure 5 (a) is the percentage of apoptosis during the growth of Tca-8113 / CDDP cells. Figure 5 (b) is a bar graph showing the percentage of apoptosis during the growth of Tca-8113 / CDDP cells.
[0053] Figure 6 These are the treatment results of Example 1 and Comparative Examples 1 to 4 on oral squamous cell carcinoma (Tca-8113 / CDDP) tumor-bearing mice.
[0054] Figure 7 The results of Example 1 and Comparative Examples 1 to 4 on the treatment of oral squamous cell carcinoma (Tca-8113 / CDDP) tumor-bearing mice, wherein Figure 7 (a) is the tumor weight, Figure 7 (b) shows the changes in body weight of mice. DETAILED DESCRIPTION
[0055] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work belong to the scope of protection of the present invention.
[0056] In a first aspect, some embodiments of the present invention provide a method for preparing a nanomedicine for treating cisplatin-resistant oral squamous cell carcinoma, comprising the following steps:
[0057] S1: Synthesize the targeting polypeptide derivative LEE011-FFERGD, the structural formula of the targeting polypeptide derivative LEE011-FFERGD is:
[0058]
[0059] S2: The targeting peptide derivative LEE011-FFERGD in S1 was co-assembled with cisplatin to synthesize the nanodrug LEE011-FFERGD / CDDP.
[0060] In the nanomedicine of the present invention, the targeted polypeptide derivative LEE011-FFERGD is co-assembled with cisplatin, wherein the targeted polypeptide derivative LEE011-FFERGD can promote the silencing of the BAG1 gene in patients with cisplatin-resistant oral squamous cell carcinoma, thereby reducing the expression of related molecules in the G1 / S process of the cell cycle, and ultimately overcoming the resistance of cisplatin-resistant patients with oral squamous cell carcinoma to cisplatin; on this basis, through the synergistic effect of cisplatin, the cisplatin assembled in the nanomedicine directly acts on the diseased part of oral squamous cell carcinoma, thereby effectively improving the therapeutic effect of the nanomedicine of the present invention on patients with resistant oral squamous cell carcinoma.
[0061] In some embodiments, the polypeptide derivative LEE011-FFERGD in S1 is obtained by solid phase peptide synthesis using 2-chlorotributyl chloride resin as a carrier and different N-Fmoc protected amino acids as raw materials.
[0062] In some embodiments, the specific conditions for assembling and synthesizing the nanodrug LEE011-FFERGD / CDDP in S2 include:
[0063] The targeting polypeptide derivative LEE011-FFERGD is dispersed in PBS buffer (phosphate buffer solution), cisplatin is added, the pH value is adjusted to neutral, and the targeting polypeptide derivative LEE011-FFERGD and cisplatin are heated until both the targeting polypeptide derivative LEE011-FFERGD and cisplatin are dissolved, and the mixture is cooled and allowed to stand to obtain the nano drug of the present invention.
[0064] In some embodiments, the concentration of the targeting polypeptide derivative LEE011-FFERGD in PBS buffer is 5 mg / mL.
[0065] In some embodiments, the molar concentration of cisplatin is 1 to 3 times the molar concentration of the targeting polypeptide derivative LEE011-FFERGD.
[0066] In some embodiments, the solution for adjusting the pH value includes an aqueous solution of sodium carbonate.
[0067] In some embodiments, the cooling temperature is 25°C-30°C.
[0068] In some embodiments, the standing time is not less than 30 minutes.
[0069] In a second aspect, some embodiments also provide nanomedicines obtained by the preparation method.
[0070] In some embodiments, the nanomedicine is in granular form with an average diameter of 60nm-80nm.
[0071] In a third aspect, some embodiments also provide the use of the nanomedicine obtained by the preparation method in treating patients with oral squamous cell carcinoma.
[0072] The following is further described in conjunction with specific embodiments.
[0073] Embodiment 1:
[0074] Synthesis of LEE011-FFERGD: Dissolve LEE011 (succinic acid) (1 g), succinic anhydride (230 mg), and DIEA (N,N-diisopropylethylamine) (297 mg) in 30 mL of dichloromethane and stir overnight. The reaction mixture was concentrated under reduced pressure. The crude product was then suspended in 30 mL of ethyl acetate, filtered, and the residue was dried to obtain LEE011-succinic acid. The targeted peptide derivatives were prepared by standard solid phase peptide synthesis (SPPS) method. Briefly, 2-chlorotributyl chloride resin was used as a carrier and various N-Fmoc-protected amino acids with side chains were used as reactants.
[0075] (1) 0.5 g of 2-chlorotributyl chloride resin was swelled in 20 mL of dry dichloromethane for 10 minutes and then the dichloromethane (DCM) was removed.
[0076] (2) After adding the first amino acid Fmoc-Asp(tBu)-OH (0.5 mmol) and reacting for 1 hour, the unreacted sites in the resin were blocked with a blocking solution (dichloromethane:methanol:N,N-diisopropylethylamine, 17:2:1 mL).
[0077] (3) Remove the protective group Fmoc with 20 mL of anhydrous N,N'-dimethylformamide (DMF) containing 20% piperidine, wash with DCM three times, and wash with DMF three times.
[0078] (4) Add N,N'-dimethylformamide, N,N-diisopropylethylamine (2 mmol), benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (1 mmol), and amino acid Fmoc-Gly-OH (1 mmol) and react for 2 hours. Then, add 20% piperidine in anhydrous DMF to remove the Fmoc protecting group of the amino acid and wash with DMF three times. The volume of N,N'-dimethylformamide added is 20 mL.
[0079] (5) According to step (4), amino acid Fmoc-Arg(Pbf)-OH, amino acid Fmoc-Glu(tBu)-OH, amino acid Fmoc-Phe-OH, and amino acid Fmoc-Phe-OH are linked to the polypeptide.
[0080] (6) Add N,N'-dimethylformamide (20 mL), LEE011-succinic acid (1 mmol), N,N-diisopropylethylamine (2 mmol), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (1 mmol) to react.
[0081] (7) The mixture was washed with DCM three times, and the peptide derivative was cleaved from the resin with 20 mL of trifluoroacetic acid. The final crude product was purified by reverse-phase high performance liquid chromatography to obtain the target compound with a yield of 71%.
[0082] Preparation of LEE011-FFERGD / CDDP nanodrug: Disperse LEE011-FFERGD (5 mg) in 1 mL PBS. Add cisplatin (1.2 mg) according to the obtained concentration. Add sodium carbonate aqueous solution (1 M) and adjust the final pH value to 7.4. Heat the suspension to a transparent solution, immediately cool to room temperature, and leave it at room temperature for half an hour to obtain the nanodrug, which is recorded as LEE011-FFERGD / CDDP.
[0083] Comparative Example 1: PBS solution was directly used, wherein the pH value of the PBS solution was in the range of 7.4, and sodium carbonate aqueous solution (1 M) was used to adjust the pH value of the PBS solution, as a blank experimental group, recorded as vehicle.
[0084] Comparative Example 2: Cisplatin was directly used and recorded as cisplatin.
[0085] Comparative Example 3: LEE011 was directly used and recorded as LEE011.
[0086] Comparative Example 4: Cisplatin and LEE011 were physically mixed, wherein cisplatin and LEE011 were directly mixed to obtain a drug, wherein the added amounts of cisplatin and LEE011 were the same as those in Example 1. Recorded as cisplatin+LEE011.
[0087] In the present invention, the drugs obtained in the examples and comparative examples were tested.
[0088] The NMR results of the intermediate product LEE011-FFERGD in Example 1 are as follows:
[0089] 1H NMR (500 MHz, DMSO) δ 8.90 (s, 1H), 8.25 (dd, J = 7.8, 2.9 Hz,2H), 8.18 (q, J = 5.2 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 7.97 – 7.91 (m, 2H),7.89 – 7.76 (m, 2H), 7.47 (t, J = 5.7 Hz, 1H), 7.34 – 7.12 (m, 11H), 6.74 (s,1H), 4.78 (p, J = 8.8 Hz, 1H), 4.61 – 4.46 (m, 2H), 4.42 – 4.34 (m, 1H), 4.34– 4.24 (m, 2H), 3.81 (dd, J = 16.9, 5.9 Hz, 1H), 3.75 – 3.53 (m, 7H), 3.21 –3.05 (m, 12H), 2.99 – 2.85 (m, 2H), 2.72 – 2.63 (m, 2H), 2.63 – 2.52 (m, 3H),2.43 – 2.32 (m, 3H), 2.29 – 2.18 (m, 3H), 2.06 – 1.90 (m, 4H), 1.83 – 1.74(m, 1H), 1.74 – 1.61 (m, 3H), 1.59 – 1.47 (m, 3H). 13C NMR (126 MHz, DMSO) δ174.02, 172.39, 172.28, 171.65, 171.49, 171.44, 171.01, 170.91, 170.29,168.52, 162.51, 156.70, 152.75, 151.51, 144.78, 141.90, 137.99, 137.93,129.15, 129.10, 128.18, 128.06, 126.34, 126.24, 114.41, 113.27, 100.94,57.01, 54.46, 54.16, 52.15, 51.97, 48.58, 48.22, 44.33, 41.51, 40.79, 40.47,38.77, 36.89, 36.78, 36.09, 34.62, 30.35, 30.12, 29.99, 29.25, 27.90, 27.26,24.84, 24.23, 17.87, 12.10. HRMS (ESI) calcd for C 62 H 78 N 17 O 14 [MH] - 1284.5920, found 1284.5918 [MH] - .
[0090] Figure 1 (a)- Figure 1 (b) is a scale with a length of 500 nm. In the present invention, the nanomedicine obtained was characterized by transmission electron microscopy for its microscopic morphology. Figure 1 (b) shows that Figure 1 (b) It can be found that the nanomedicine obtained by the present invention is in a dispersed granular structure, and the average diameter of the nanoparticles of the present invention is 60nm-80nm. Figure 2 (a)- Figure 2 (b) Verify that Figure 2 (b) is the result of dynamic light scattering test, which further confirmed that the average diameter of nanomedicine is between 60nm-80nm.
[0091] exist Figure 3 (a) - Figure 3 (b) are the circular dichroism results of the intermediate product LEE011-FFERGD and the final product LEE011-FFERGD / CDDP in Example 1. Figure 3(b) shows that the final product nanomedicine has a positive peak at 210nm-230nm and a negative peak near 200nm, indicating that the secondary structure of the polypeptide derivative is a random Coli configuration. Figure 3 (b) with Figure 3 (a) Comparison also verifies that the intermediate product LEE011-FFERGD in the present invention successfully assembled with cisplatin to form a product with a random Coli configuration.
[0092] The examples and comparative examples were subjected to cell clone formation experiments, and the experimental results are as follows Figure 4 As shown. Figure 4 It can be found in (a) that compared with the comparative example, the nanodrug obtained by assembling LEE011-FFERGD and cisplatin acts on Tca-8113 / CDDP cells (oral squamous cell carcinoma cells), which greatly reduces the number of oral squamous cell carcinoma cells. Figure 4 (b) Comparative verification of the number of corresponding intuitive cell clones. It can be seen that the drug obtained by the present invention can induce apoptosis of Tca-8113 / CDDP cells under the combined action of LEE011-FFERGD and cisplatin. Figure 5 (a)- Figure 5 (b) The results of the cell apoptosis experiment showed that the drug obtained by the present invention had the most significant effect in inducing early and late apoptosis of Tca-8113 / CDDP cells in vitro.
[0093] The drugs of the examples and comparative examples were subjected to in vivo experiments. Tca-8113 / CDDP cells were implanted into the floor of the mouth of nude mice to establish an oral squamous cell carcinoma transplantation model and used for in vivo tumor inhibition experiments. Figure 6 As shown, it can be obtained from Figure 6 It is found that the drug obtained by the present invention can significantly inhibit tumor growth in tumor-bearing mice, so the tumor volume is smaller, while the tumor volume in other comparative examples is larger. Figure 7 (a)- Figure 7 (b) To verify, Figure 7 (a) The tumor masses of Example 1 were significantly lower than those of Comparative Examples 1 to 4, demonstrating that the Chinese medicine of the present invention can effectively inhibit the growth of oral squamous cell carcinoma. Figure 7 In (b), compared with Example 4, the weight loss of mice in Example 1 of the present invention is the most significant, indicating that LEE011 alone or in combination with cisplatin has greater toxicity in vivo. The weight of mice in Example 1 did not decrease significantly during the treatment period, proving that the present invention exhibits good pharmacological safety characteristics in vivo.
[0094] In summary, the nanomedicine obtained by the present invention not only has a significant tumor inhibition effect, but also exhibits good pharmacological safety characteristics in vivo, and can be used to treat patients with oral squamous cell carcinoma.
[0095] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the technical solutions of the embodiments of the present invention.
Claims
1. Use of a cisplatin-resistant nanomedicine for oral squamous cell carcinoma in the preparation of a drug for treating drug resistance in patients with oral squamous cell carcinoma, characterized in that: The preparation method of the nano drug comprises the following steps: S1: Synthesize the targeting polypeptide derivative LEE011-FFERGD, the structural formula of the targeting polypeptide derivative LEE011-FFERGD is: S2: The targeted peptide derivative LEE011-FFERGD in S1 was co-assembled with cisplatin to synthesize the nanodrug LEE011-FFERGD / CDDP; The specific conditions for assembling and synthesizing the nanodrug LEE011-FFERGD / CDDP in S2 include: The targeting peptide derivative LEE011-FFERGD is dispersed in PBS buffer, cisplatin is added, the pH value is adjusted to neutral, and the targeting peptide derivative LEE011-FFERGD and cisplatin are heated until both the targeting peptide derivative LEE011-FFERGD and cisplatin are dissolved, and the mixture is cooled and allowed to stand to obtain a nano drug; The concentration of the targeting peptide derivative LEE011-FFERGD in PBS buffer is 5 mg / mL; The concentration of cisplatin in PBS buffer was 1.2 mg / mL.
2. The use according to claim 1, characterized in that: The targeted peptide derivative LEE011-FFERGD in S1 is obtained by solid phase peptide synthesis using 2-chlorotributyl chloride resin as a carrier and different N-Fmoc protected amino acids as raw materials.
3. The use according to claim 1, characterized in that: The cooling temperature is 25°C-30°C.
4. The use according to claim 1, characterized in that: The standing time is not less than 30 min.
5. The use according to claim 2, characterized in that: The steps of the solid phase synthesis method are: S11: reacting the swollen 2-chlorotributyl chloride resin with amino acid Fmoc-Asp(tBu)-OH, adding blocking solution; removing the protecting group Fmoc, and washing; S12: adding N,N'-dimethylformamide, N,N-diisopropylethylamine, benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate, and amino acid Fmoc-Gly-OH to react, removing the protecting group Fmoc, and washing; S13: repeat the step of S12 to sequentially connect the amino acid Fmoc-Arg(Pbf)-OH, the amino acid Fmoc-Glu(tBu)-OH, the amino acid Fmoc-Phe-OH, and the amino acid Fmoc-Phe-OH to the polypeptide; S14: adding N,N'-dimethylformamide, LEE011-succinic acid, N,N-diisopropylethylamine, and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate to react; S15: washing and cleavage, cleaving the targeted peptide derivative LEE011-FFERGD from the resin.
6. The use according to claim 5, characterized in that: The blocking solution is composed of dichloromethane, methanol, and N,N-diisopropylethylamine, and the volume ratio of dichloromethane, methanol, and N,N-diisopropylethylamine is 17:2:1; The amount of the amino acid Fmoc-Asp(tBu)-OH in S11 is 0.4 mmol -0.6 mmol; The specific process of removing the protective group Fmoc in S11 includes using 19mL-21mL of anhydrous N,N'-dimethylformamide containing piperidine to react for 0.5h-1h, and the mass fraction of piperidine in the anhydrous N,N'-dimethylformamide is 20%; in the washing in S11, washing with dichloromethane for 3-5 times and then washing with N,N'-dimethylformamide for 3-5 times; In the step S12, washing is performed with N,N'-dimethylformamide for 3-5 times; The molar ratio of N,N-diisopropylethylamine, benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate, and amino acid Fmoc-Gly-OH in S12 is 2:1:1, and the molar ratio of amino acid Fmoc-Gly-OH is 0.5 mmol -2 mmol; The molar ratio of N,N-diisopropylethylamine, benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate, and LEE011-succinic acid in S14 is 2:1:1, and the molar ratio of LEE011-succinic acid is 0.5 mmol-2 mmol; Furthermore, the method of washing and cutting in S15 to separate the polypeptide derivative includes first washing with dichloromethane for 3-5 times, and then adding 19mL-21mL trifluoroacetic acid for cutting for 0.5-1h to cut the targeted polypeptide derivative LEE011-FFERGD from the resin.
7. The use according to claim 1, characterized in that: The nano drug is in granular form with an average diameter of 60nm-80nm.
